Cervical cancer is one of the most common malignant tumors in women worldwide, and its death rate is increasing year by year and its incidence is getting younger, which is a serious threat to women’s health. Although surgical treatment for cervical cancer is becoming more and more mature, it has not achieved satisfactory efficacy for patients in the middle and late stages. Targeted tumor therapy is a treatment targeting specific molecules in tumor cells, which can specifically combine with oncogenic sites and have obvious advantages such as high specificity and low side effects. Among them, tumor-targeted therapeutic drugs using nanomaterials as carriers have become an important direction and development trend of antitumor drugs. Tumor-targeted drugs can be divided into five categories according to their mechanisms of action: (1) signal transduction blockade; (2) inhibition of vascularization and anti-metastasis; (3) cell cycle regulation; (4) gene therapy; and (5) immune vaccine therapy. Although a few tumor-targeted therapeutic agents have entered clinical trials or clinical applications, there are still many problems; in addition, biological and physical targeting therapies have also shown their advantages and disadvantages. What are the molecular targeted therapeutic drugs for cervical cancer? 1.Vascular endothelial growth factor inhibitor VEGF is a secretory glycoprotein that specifically stimulates vascular endothelial cell proliferation, migration and revascularization through paracrine and autocrine modes after binding to tyrosine kinase receptors, which is essential for tumor growth and metastasis. It was found that there was a significant positive correlation between VEGF mRNA expression level and the clinicopathological stage, pathological differentiation, lymph node metastasis, tumor diameter, and deep muscle infiltration of cervical cancer (P < 0.05). Thus, VEGF and its receptors have become the main targets of antitumor therapy. Currently, bevacizumab (avastin) and pazopanib are the main VEGF-targeting drugs used in clinical practice, which can inhibit tumor cell growth or metastasis by blocking the formation of microvessels. Bevacizumab has been approved by the U.S. FDA for the treatment of metastatic colorectal cancer, making it the first angiogenesis inhibitor approved for marketing, while VEGF antagonists are in preclinical studies for the treatment of cervical cancer and clinical applications at home and abroad. 2.Epidermal growth factor receptor antagonist EGFR is a transmembrane glycoprotein that can activate tyrosine kinase, control cell division and proliferation, promote angiogenesis and tumor metastasis, and is closely related to the formation and development of tumors. EGFR was found to be significantly overexpressed in cervical cancer tissues, and EGFR was the first growth factor receptor to be targeted for tumor therapy. EGFR antagonists are divided into anti-EGFR monoclonal antibodies and EGFR small molecule tyrosine kinase inhibitors (TKIs), both of which can inhibit tumor cell proliferation and induce apoptosis by inhibiting EGFR autophosphorylation and downstream signaling. Anti-EGFR monoclonal antibodies include cetuximab, panitumumab (ABX-EGF), and trastuzumab, while TKIs include the reversible gefitinib, erlotinib, and the irreversible inhibitor EKB569. The tyrosine kinase inhibitor gefitinib is the most widely studied oral small molecule antitumor drug to date, and gefitinib can effectively control the disease progression in stage II treatment of cervical cancer. 3.Signal transduction blocking drugs Mammalian target of rapamycin (mTOR) can regulate tumor growth and cell reproduction, is involved in protein synthesis, and is the main target of PI3K/Akt pathway. mTOR abnormal activation can lead to many tumorigenesis, and its signaling pathway abnormal regulation contributes to tumor cell proliferation and survival of cervical cancer cells. It has been observed that mTOR signaling pathway is activated in cervical cancer, and the main mTOR kinase inhibitors are CCI-779. In addition, there are many genes related to apoptosis signaling pathway in human body, such as p53, bcl-2, mdm-2 genes, etc., which also become good targets for cervical cancer treatment. For example, recombinant human adenovirus p53 injection (gendicine) is a good targeted antitumor drug with broad-spectrum anticancer effects. Histone deacetylases are a class of proteases that are related to the regulation of gene expression and structural modification of chromosomes. It has been found that HDAC inhibitors can induce the accumulation of acetylated histones in the chromatin P21WAF1 gene of cervical cancer cells and inhibit the expression of malignant phenotype genes associated with cervical cancer cell lines. Drugs that target histone deacetylases include valproic acid. In addition, there are a wide variety of inhibitors that use cell cycle protein-dependent kinases as targets for tumor therapy. Gene loaded nanoparticle injection is the first targeted antitumor drug approved for marketing in the cell cycle regulator class and has been widely used for the treatment of various intractable cancers. 5.Other targeted therapeutic agents The enhanced expression of cyclooxygenase-2 is related to the pathogenic process of many types of tumors. Cyclooxygenase inhibitors are mainly represented by celecoxib. MMP inhibitors (MMPI) are mainly represented by paramastat and pramastat. There are also some anti-HER-2 monoclonal antibodies, such as herceptin; anti-CD20 monoclonal antibodies, such as rituximab; IGFR-1 kinase inhibitors, such as NVP-AEW541; ubiquitin-proteasome inhibitors (such as bortezomib), etc. In addition, many new tumor-targeting drugs such as small molecule tyrosine kinase inhibitors and antisense mRNA inhibitors have also become hot spots in the research of cervical cancer gene therapy. Warm tip: Please refer to the doctor's consultation for the specific medication.